Ophthalmic Brachytherapy

In many centres, brachytherapy is the first choice of treatment for uveal melanomas. This modality is also useful for some retinoblastomas and conjunctival tumors. With this form of radiotherapy, a radioactive plaque containing ruthenium-106 or iodine-125 is sutured to the wall of the eye, adjacent to the tumor, and left in place for several days until the required dose of radiation has been delivered.

Eckert & Ziegler BEBIG offers a series of reliable products for temporary brachytherapy of eye cancers. The company is the manufacturer of Ru-106 (Ruthenium-106) Eye Applicators used to treat uveal melanoma and retinoblastoma.
The  product portfolio also includes the COMS Eye Applicators used together with IsoSeed® I-125.

For more information, please see www.bebig.com.

Eckert & Ziegler
BEBIG GmbH

Robert-Rössle-Str. 10
13125 Berlin

E-Mail: info@dont-want-spam.bebig.com
www.bebig.com

HOW TO FIND US